Literature DB >> 24062884

Conditioning the heart to prevent myocardial reperfusion injury during PPCI.

Derek J Hausenloy1.   

Abstract

For patients presenting with a ST-segment elevation myocardial infarction (STEMI), early myocardial reperfusion by primary percutaneous coronary intervention (PPCI) remains the most effective treatment strategy for limiting myocardial infarct size, preserving left ventricular systolic function, and preventing the onset of heart failure. Recent advances in PCI technology to improve myocardial reperfusion and the introduction of novel anti-platelet and anti-thrombotic agents to maintain the patency of the infarct-related coronary artery continue to optimize PPCI procedure. However, despite these improvements, STEMI patients still experience significant major adverse cardiovascular events. One major contributing factor has been the inability to protect the heart against the lethal myocardial reperfusion injury, which accompanies PPCI. Past attempts to translate cardioprotective strategies, discovered in experimental studies to prevent lethal myocardial reperfusion injury, into the clinical setting of PPCI have been disappointing. However, a number of recent proof-of-concept clinical studies suggest that the heart can be 'conditioned' to protect itself against lethal myocardial reperfusion injury, as evidenced by a reduction in myocardial infarct size. This can be achieved using either mechanical (such as ischaemic postconditioning, remote ischaemic preconditioning, therapeutic hypothermia, or hyperoxaemia) or pharmacological (such as cyclosporin-A, natriuretic peptide, exenatide) 'conditioning' strategies as adjuncts to PPCI. Furthermore, recent developments in cardiac magnetic resonance (CMR) imaging can provide a non-invasive imaging strategy for assessing the efficacy of these novel adjunctive therapies to PPCI in terms of key surrogate clinical endpoints such as myocardial infarct size, myocardial salvage, left ventricular ejection fraction, and the presence of microvascular obstruction or intramyocardial haemorrhage. In this article, we review the therapeutic potential of 'conditioning' to protect the heart against lethal myocardial reperfusion injury in STEMI patients undergoing PPCI.

Entities:  

Keywords:  Ischaemic postconditioning; ST-segment elevation myocardial infarction; myocardial reperfusion injury; primary percutaneous coronary intervention; remote ischaemic perconditioning

Year:  2012        PMID: 24062884      PMCID: PMC3760559          DOI: 10.1177/2048872612438805

Source DB:  PubMed          Journal:  Eur Heart J Acute Cardiovasc Care        ISSN: 2048-8726


  84 in total

1.  Ischemic preconditioning at a distance: reduction of myocardial infarct size by partial reduction of blood supply combined with rapid stimulation of the gastrocnemius muscle in the rabbit.

Authors:  Y Birnbaum; S L Hale; R A Kloner
Journal:  Circulation       Date:  1997-09-02       Impact factor: 29.690

2.  Intermittent peripheral tissue ischemia during coronary ischemia reduces myocardial infarction through a KATP-dependent mechanism: first demonstration of remote ischemic perconditioning.

Authors:  M R Schmidt; M Smerup; I E Konstantinov; M Shimizu; J Li; M Cheung; P A White; S B Kristiansen; K Sorensen; V Dzavik; A N Redington; R K Kharbanda
Journal:  Am J Physiol Heart Circ Physiol       Date:  2006-12-15       Impact factor: 4.733

3.  Reperfusion conditions: importance of ensuring gentle versus sudden reperfusion during relief of coronary occlusion.

Authors:  F Okamoto; B S Allen; G D Buckberg; H Bugyi; J Leaf
Journal:  J Thorac Cardiovasc Surg       Date:  1986-09       Impact factor: 5.209

4.  A pilot study of rapid cooling by cold saline and endovascular cooling before reperfusion in patients with ST-elevation myocardial infarction.

Authors:  Matthias Götberg; Göran K Olivecrona; Sasha Koul; Marcus Carlsson; Henrik Engblom; Martin Ugander; Jesper van der Pals; Lars Algotsson; Håkan Arheden; David Erlinge
Journal:  Circ Cardiovasc Interv       Date:  2010-08-24       Impact factor: 6.546

5.  Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.

Authors:  Hans Erik Bøtker; Rajesh Kharbanda; Michael R Schmidt; Morten Bøttcher; Anne K Kaltoft; Christian J Terkelsen; Kim Munk; Niels H Andersen; Troels M Hansen; Sven Trautner; Jens Flensted Lassen; Evald Høj Christiansen; Lars R Krusell; Steen D Kristensen; Leif Thuesen; Søren S Nielsen; Michael Rehling; Henrik Toft Sørensen; Andrew N Redington; Torsten T Nielsen
Journal:  Lancet       Date:  2010-02-27       Impact factor: 79.321

6.  Effect of erythropoietin as an adjunct to primary percutaneous coronary intervention: a randomised controlled clinical trial.

Authors:  Andrew J Ludman; Derek M Yellon; Jonathan Hasleton; Cono Ariti; Girish Ganesha Babu; Edney Boston-Griffiths; Vinod Venugopal; Malcolm Walker; Diana Holdright; Howard Swanton; Tom Crake; David Brull; James C Moon; Rajesh Puranik; Vivek Muthurangu; Vivek Mutharangu; Andrew Taylor; Derek J Hausenloy
Journal:  Heart       Date:  2011-10       Impact factor: 5.994

7.  Human atrial natriuretic peptide and nicorandil as adjuncts to reperfusion treatment for acute myocardial infarction (J-WIND): two randomised trials.

Authors:  Masafumi Kitakaze; Masanori Asakura; Jiyoong Kim; Yasunori Shintani; Hiroshi Asanuma; Toshimitsu Hamasaki; Osamu Seguchi; Masafumi Myoishi; Tetsuo Minamino; Takahiro Ohara; Yoshiyuki Nagai; Shinsuke Nanto; Kouki Watanabe; Shigeru Fukuzawa; Atsushi Hirayama; Natsuki Nakamura; Kazuo Kimura; Kenshi Fujii; Masaharu Ishihara; Yoshihiko Saito; Hitonobu Tomoike; Soichiro Kitamura
Journal:  Lancet       Date:  2007-10-27       Impact factor: 79.321

8.  Impact of myocardial haemorrhage on left ventricular function and remodelling in patients with reperfused acute myocardial infarction.

Authors:  Javier Ganame; Giancarlo Messalli; Steven Dymarkowski; Frank E Rademakers; Walter Desmet; Frans Van de Werf; Jan Bogaert
Journal:  Eur Heart J       Date:  2009-04-03       Impact factor: 29.983

Review 9.  Why do we still not have cardioprotective drugs?

Authors:  James M Downey; Michael V Cohen
Journal:  Circ J       Date:  2009-06-09       Impact factor: 2.993

Review 10.  Interaction of cardiovascular risk factors with myocardial ischemia/reperfusion injury, preconditioning, and postconditioning.

Authors:  Peter Ferdinandy; Rainer Schulz; Gary F Baxter
Journal:  Pharmacol Rev       Date:  2007-11-29       Impact factor: 25.468

View more
  7 in total

1.  Randomized controlled trial of remote ischemic preconditioning and atrial fibrillation in patients undergoing cardiac surgery.

Authors:  Amir S Lotfi; Hossein Eftekhari; Auras R Atreya; Ananth Kashikar; Senthil K Sivalingam; Miguel Giannoni; Paul Visintainer; Daniel Engelman
Journal:  World J Cardiol       Date:  2016-10-26

2.  The Inflammatory Cytokine IL-3 Hampers Cardioprotection Mediated by Endothelial Cell-Derived Extracellular Vesicles Possibly via Their Protein Cargo.

Authors:  Claudia Penna; Saveria Femminò; Marta Tapparo; Tatiana Lopatina; Kari Espolin Fladmark; Francesco Ravera; Stefano Comità; Giuseppe Alloatti; Ilaria Giusti; Vincenza Dolo; Giovanni Camussi; Pasquale Pagliaro; Maria Felice Brizzi
Journal:  Cells       Date:  2020-12-23       Impact factor: 6.600

3.  Ozone protects cardiomyocytes against ischemia/reperfusion injury: Regulating the heat shock protein 70 (HPS70) expression through activating the JAK2/STAT3 Pathway.

Authors:  Shenglong Yu; Huizhuang Guo; Yi Luo; Hanwei Chen
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

Review 4.  The surging role of Chromogranin A in cardiovascular homeostasis.

Authors:  Bruno Tota; Tommaso Angelone; Maria C Cerra
Journal:  Front Chem       Date:  2014-08-14       Impact factor: 5.221

5.  EMMPRIN-Targeted Magnetic Nanoparticles for In Vivo Visualization and Regression of Acute Myocardial Infarction.

Authors:  Irene Cuadrado; Maria Jose Garcia Miguel Piedras; Irene Herruzo; Maria Del Carmen Turpin; Borja Castejón; Paula Reventun; Ana Martin; Marta Saura; Jose Luis Zamorano; Carlos Zaragoza
Journal:  Theranostics       Date:  2016-02-15       Impact factor: 11.556

6.  Out-of-hospital initiation of hypothermia in ST-segment elevation myocardial infarction: a randomised trial.

Authors:  Christoph Testori; Dietrich Beitzke; Andreas Mangold; Fritz Sterz; Christian Loewe; Christoph Weiser; Thomas Scherz; Harald Herkner; Irene Lang
Journal:  Heart       Date:  2018-10-25       Impact factor: 5.994

7.  CBL knockdown protects cardiomyocytes against hypoxia-reoxygenation injury by downregulating GRB2 expression.

Authors:  Zhengbing Lv; Xiaojia Luo; Biying Hong; Qiran Ye; Jianxiong Liu; Yongmei Hu
Journal:  Exp Ther Med       Date:  2022-01-03       Impact factor: 2.447

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.